

Summary of Utilization Management (UM) Program Changes

January 2021

Brand Name	Generic Name	Utilization Update Summary	Type	Effective Date
<i>Bafiertam (in Multiple Sclerosis guideline)</i>	monomethyl fumarate	<p>Indicated for the treatment of relapsing forms of multiple sclerosis.</p> <p>Initial criteria requires:</p> <ol style="list-style-type: none"> 1) Diagnosis of relapsing forms of multiple sclerosis 2) Trial and failure to at least TWO of the following drugs: Aubagio, Avonex, Copaxone/Glatopa, Extavia, Gilenya, Tecfidera 3) OR for continuation of therapy 4) Prescribed by a neurologist. 	Update	3/15/2021
<i>Kynmobi (added to Apomorphine guideline)</i>	apomorphine	<p>Initial criteria requires:</p> <ol style="list-style-type: none"> 1) Diagnosis of advanced Parkinson's disease 2) Patient is experiencing acute intermittent hypomobility (defined as "off" episodes characterized by muscle stiffness, slow movements, or difficulty starting movements) 3) Used in combination with other medications for the treatment of Parkinson's disease (e.g., carbidopa/levodopa, pramipexole, ropinirole, etc.) 4) Not used with any 5-HT3 antagonist (e.g., ondansetron, granisetron, dolasetron, palonosetron, alosetron) 5) Prescribed by a neurologist. 	Update	3/15/2021
<i>Oriahnn</i>	elagolix; elagolix / estradiol / norethindrone acetate	<p>Oriahnn is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.</p> <p>Initial criteria requires:</p> <ol style="list-style-type: none"> 1) Diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) 2) Patient is premenopausal 3) One of the following: a) history of inadequate control of bleeding following a trial of at least 3 months, to one of the following: 	New	3/15/2021

		combination (estrogen/progestin) oral contraceptive, progestins, tranexamic acid OR b) patient has had a previous interventional therapy to reduce bleeding, 4) Treatment duration of therapy has not exceeded a total of 24 months.		
<i>Uplizna</i>	Inebilizumab-cdon	Uplizna is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. Initial criteria requires: 1) Diagnosis of neuromyelitis optica spectrum disorder (NMOSD) 2) Patient is anti-aquaporin-4 (AQP4) antibody positive 3) Prescribed by a neurologist.	New	3/15/2021
<i>Zepzelca</i>	lurbinectidin	Zepzelca is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Initial criteria requires: 1) diagnosis of metastatic small cell lung cancer (SCLC), disease has progressed on or after platinum-based chemotherapy (e.g., carboplatin, cisplatin, oxaliplatin) 2) Prescribed by an oncologist.	New	3/15/2021
<i>Fintepla</i>	fenfluramine	Fintepla is indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older. Initial criteria requires: 1) Diagnosis of seizures associated with Dravet syndrome 2) Prescribed by a neurologist.	New	3/15/2021
<i>Crysvita</i>	burosumab-twza	New indication for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized	Update	3/15/2021

		<p>in adult and pediatric patients 2 years of age and older.</p> <p>Initial criteria for the new indication requires:</p> <ol style="list-style-type: none"> 1) Diagnosis of FGF23-related hypophosphatemia in Tumor-Induced Osteomalacia (TIO) Tumor could not be cured or localized with surgery 2) Patient is at least 2 years of age 3) Trial and failure of conventional therapy with both of the following: phosphate supplementation and vitamin D analog-based therapy (e.g., calcitriol, paricalcitol, doxercalciferol) 4) Prescribed by an oncologist or an endocrinologist.. 		
<i>Cyramza (in Oncology Injectable guideline)</i>	ramucirumab	<p>Indicated in combination with erlotinib, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.</p> <p>The individual Cyramza guideline will be retired and the drug will be included in the general Oncology Injectable guideline. Criteria requires an FDA-approved indication or meets off-label administrative guideline criteria and prescribed by an oncologist.</p>	Update	3/15/2021
<i>Ilaris</i>	canakinumab	<p>New indication for treatment of Still's disease, including Adult-Onset Still's Disease.</p> <p>Initial criteria for the new indication requires:</p> <ol style="list-style-type: none"> 1) Diagnosis of Still's Disease, including Adult-Onset Still's Disease 2) Trial and failure of one of the following: corticosteroids, methotrexate, or a nonsteroidal anti-inflammatory drug (NSAID) 3 Patient not receiving concomitant treatment with a tumor necrosis factor inhibitor 	Update	3/15/2021

		(TNF) and not receiving concomitant treatment with an interleukin-1 inhibitor (IL-1) 4) Prescribed by a rheumatologist.		
<i>Cosentyx</i>	secukinumab	New indication for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Initial criteria for the new indication requires: 1) Diagnosis of nr-axSpA 2) Objective signs of inflammation 3) Trial and failure of two NSAIDs 4) Trial and failure to BOTH Cimzia AND Taltz 5) Prescribed by a rheumatologist.	Update	3/15/2021
<i>Taltz</i>	ixekizumab	New indication for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Initial criteria for the new indication requires: 1) Diagnosis of nr-axSpA 2) Objective signs of inflammation 3) Trial and failure of two NSAIDs 4) Trial and failure to Cimzia 5) Prescribed by a rheumatologist.	Update	3/15/2021
<i>Tazverik</i>	tazemetostat	New indication for 1: Treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and 2: treatment of adult patients with R/R FL who have no satisfactory alternative treatment options Initial criteria for the new indication requires: 1) Diagnosis of follicular lymphoma 2) disease is one of the following: relapsed or refractory 3) Prescribed by an oncologist or hematologist.	Update	3/15/2021
<i>Xpovio</i>	selinexor	New indication for the Treatment of adult patients with relapsed or	Update	3/15/2021

		<p>refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.</p> <p>Initial criteria for the new indication requires: 1) Diagnosis of ONE of the following: a. Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS) b. Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma; 2) Patient has previously received at least two types of systemic therapy 3) Prescribed by or in consultation with an oncologist/hematologist.</p>		
<i>CGRP Inhibitors (Aimovig, Emgality, Ajovy, Vyepti, Nurtec, Ubrelvy)</i>	various	<p>Update language for concomitant use criteria. For injectable products, Aimovig, Emgality, Avjoy, and Vyepti, the requirement will be "Medication will not be used in combination with another injectable CGRP inhibitor." For oral products, Nurtec and Ubrelvy, the criteria will be updated to "Medication will not be used in combination with another oral CGRP inhibitor." <i>(This allows members to be prescribed both a preventive injectable drug and an oral acute treatment drug.)</i></p>	Update	3/15/2021
<i>Reyvow</i>	lasmiditan	<p>Criteria will now require a trial and failure, contraindication, or intolerance to BOTH Nurtec and Ubrelvy.</p>	Update	3/15/2021
<i>Harvoni</i>	ledipasvir-sofosbuvir	<p>Update on sections for decompensated cirrhosis patients. Align with rest of guideline and removed allowance for continuation of ledipasvir/sofosbuvir therapy in the decompensated cirrhosis criteria sections since patients only require a trial of brand Eplclusa or Harvoni. Patients currently receiving ledipasvir/sofosbuvir may</p>	Update	3/15/2021

		continue therapy with brand Harvoni.		
<i>Entyvio</i>	vedolizumab	Patients currently taking Entyvio for ulcerative colitis or Crohn's disease may continue the drug without a trial of specified biologic drugs.	Update	3/15/2021
<i>Infliximab (Avsola and Remicade)</i>	infliximab	For the treatment of Sarcoidosis, Inflectra and Renflexis must be tried before Avsola or Remicade (all are infliximab). The prescriber can now be a dermatologist or ophthalmologist in addition to the pulmonologist that was originally required.	Update	3/15/2021